Skip to content

Geron GERN Net Investment in Lease

Net Investment in Lease at other companies

Immunome logo
ImmunomeIMNM
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
Celcuity logo
CelcuityCELC
Tango Therapeutics logo
Tango TherapeuticsTNGX
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$878.88M-8.6%
Enterprise value$964.15M-6.2%
P/S4.7×-172×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's net investment in lease?
Geron (GERN) reported net investment in lease of $1.96M in Q1 2026.
How has Geron's net investment in lease changed year-over-year?
Geron's net investment in lease decreased by 27.6% year-over-year, from $2.7M to $1.96M.
What is the long-term trend for Geron's net investment in lease?
Over 5 years (2020 to 2025), Geron's net investment in lease has grown at a -16.5% compound annual growth rate (CAGR), from $5.3M to $2.15M.